Roche Holding sets July date for half year results, analysts’ view on the stock stays constructive

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:18.

Roche Holding (CH0012032048) has set 23 July 2026 as the date for its half year 2026 results release and investor presentation, with publication scheduled before the opening of SIX Swiss Exchange according to the company’s latest investor update.The official Roche investor invitation details the timing of the release and webinar.

Half year numbers due in late July

In its 23 June invitation, Roche states that it will publish the half year 2026 report on Thursday, 23 July 2026 at 07:00 CEST, corresponding to 06:00 BST and 01:00 EDT, before trading on SIX in Zurich begins.The investor update also lists the detailed release schedule for different time zones.

The group plans an investor webinar from 14:00 to 15:45 CEST on the same day, including management presentations and a Q&A session with analysts and investors.Roche names several investor relations contacts for Europe and North America in the announcement.

Analyst consensus shows upside potential

Consensus data for the Roche participation shares indicate that 18 analysts currently cover the stock, with an average rating in the Buy range and a split of nine Buy, seven Hold and two Sell recommendations.Investing.com’s consensus overview summarizes the distribution.

The same overview shows an average 12-month price target of 358.83 Swiss francs for the Roche participation, with individual estimates ranging from 230 to 428 Swiss francs and implying a double-digit percentage upside from recent levels.The consensus data quantify the potential upside that analysts currently see in the shares.

The products behind Roche’s revenue

Roche generates its revenue with a combination of prescription medicines and diagnostics, including oncology therapies such as the monoclonal antibody rituximab, marketed under the brand name MabThera in Europe and Rituxan in the United States.Roche’s product information for MabThera describes its approved uses in oncology and autoimmune diseases.

Where the Roche shares trade today

Roche Holding shares (CH0012032048) last traded on 2026-06-22 at 324.70 Swiss francs on SIX Swiss Exchange in Zurich, according to recent quote data.MarketScreener’s Roche quote page reported the closing level in Swiss francs.

This article is for informational purposes only and does not constitute investment advice, an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a professional advisor before making investment decisions.